ライフサイエンスコーパス: veno-occlusive

1 ty, any infection, organ failure, or hepatic veno-occlusive disease (1-year cumulative incidence, 71%

2 sed as a common mechanism leading to hepatic veno-occlusive disease (HVOD).

3 8-5.5), GVHD (OR, 2.4; 95% CI, 1.8-3.3), and veno-occlusive disease (OR, 2.2; 95% CI, 1.4-3.6).

4 Low L-Ficolin was associated with hepatic veno-occlusive disease (P = .0053, AUC = 0.80).

5 Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonar

6 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

7 Pulmonary veno-occlusive disease (PVOD) is an uncommon form of pul

8 s (n=12) and patients with primary pulmonary veno-occlusive disease (PVOD; n=17).

9 en successfully used to treat severe hepatic veno-occlusive disease (sVOD) with multiorgan failure (M

10 Rates of veno-occlusive disease (VOD) and thrombotic microangiopa

11 bstruction syndrome (SOS), previously called veno-occlusive disease (VOD) can be a difficult problem

12 We noted an excess of veno-occlusive disease (VOD) in a clinical trial, and re

13 Hepatic veno-occlusive disease (VOD) is a common complication of

14 Hepatic veno-occlusive disease (VOD) is one of the most serious

15 Hepatic veno-occlusive disease (VOD) is the most common of the r

16 Veno-occlusive disease (VOD) is the most common regimen-

17 Hepatic veno-occlusive disease (VOD) is the most serious regimen

18 Veno-occlusive disease (VOD) is the third leading cause

19 One patient treated at 9 mg/m2 developed veno-occlusive disease (VOD) of the liver and defined th

20 The incidence of hepatic veno-occlusive disease (VOD) was 5% for IV-BU and 1% wit

21 Hepatic veno-occlusive disease (VOD), also called sinusoidal obs

22 ibrotide for the treatment of severe hepatic veno-occlusive disease (VOD), showing a 23% improvement

23 mg/m(2) per day after recognition of hepatic veno-occlusive disease (VOD).

24 had dose limiting toxicity (DLT), including veno-occlusive disease (VOD).

25 Rates of veno-occlusive disease and interstitial pneumonitis were

26 tioned well initially, the patient developed veno-occlusive disease and required repeat transplantati

27 irected deletion of Aplnr manifest pulmonary veno-occlusive disease and right heart failure, detectab

28 sease, organ failure, infections, or hepatic veno-occlusive disease between groups.

29 ary hypertension and differentiate pulmonary veno-occlusive disease from pulmonary arterial hypertens

30 was also a trend toward an increased risk of veno-occlusive disease in patients with high ferritin.

31 Pulmonary veno-occlusive disease is caused by excessive cell proli

32 Veno-occlusive disease occurred twice with cyclophospham

33 No additional cases of veno-occlusive disease occurred.

34 Severe veno-occlusive disease of the liver occurred in 9 (21%)

35 Additionally, 95 patients developed veno-occlusive disease of the liver.

36 ificant acute graft-versus-host disease, and veno-occlusive disease of the liver.

37 the initiation of pulmonary vasodilators in veno-occlusive disease often leads to increased mortalit

38 otaline administration led to severe hepatic veno-occlusive disease on day 6.

39 lantation-related mortality; acute toxicity (veno-occlusive disease or acute graft versus-host diseas

40 Treosulfan causes less veno-occlusive disease than busulfan and does not requir

41 ary ERG and APLNR in patients with pulmonary veno-occlusive disease undergoing lung transplantation w

42 n and melphalan group had Bearman grades 1-3 veno-occlusive disease versus 21 (9%) of 239 in the carb

43 The incidence of veno-occlusive disease was 40% (13 of 32 patients) in pl

44 l recessive primary immunodeficiency disease veno-occlusive disease with immunodeficiency syndrome (V

45 elopment of sinusoidal obstruction syndrome (veno-occlusive disease) and by total serum bilirubin lev

46 ction (presenting as the syndrome of hepatic veno-occlusive disease) are all associated with signific

47 nusoidal obstruction syndrome (also known as veno-occlusive disease) in patients during study treatme

48 d $20,500, respectively), whereas infection, veno-occlusive disease, acute graft-versus-host disease,

49 nary capillary hemangiomatosis and pulmonary veno-occlusive disease, an autosomal recessively inherit

50 and 3 months of age as a result of pulmonary veno-occlusive disease, capillary hemorrhage, and pancyt

51 vely evaluated for the clinical diagnosis of veno-occlusive disease, the occurrence of acute graft-ve

52 17 patients (3%) had hepatic veno-occlusive disease.

53 is crucial for the development of pulmonary veno-occlusive disease.

54 transaminase and bilirubin without signs of veno-occlusive disease.

55 dysfunction, and a high frequency of hepatic veno-occlusive disease.

56 eveloped severe hepatotoxicity suggestive of veno-occlusive disease.

57 Two patients had reversible hepatic veno-occlusive disease.

58 used as therapy for Budd-Chiari syndrome and veno-occlusive disease.

59 or of 100-day mortality was the diagnosis of veno-occlusive disease.

60 acteristic that predicted the development of veno-occlusive disease.

61 ients with a clinical diagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

62 4 gene (EIF2AK4) are described in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

63 opathic and heritable PAH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

64 athic or heritable PAH and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatos

65 erapy; (2) posttransplant fever; (3) hepatic veno-occlusive disease; and (4) use of posttransplant gr

66 Mesenteric inflammatory veno-occlusive disorder (MIVOD) is a rare variety of inf

67 Veno-occlusive liver disease of any grade occurred in 15

68 Veno-occlusive liver disease was a major adverse event a